QNRX VS CYCC Stock Comparison

Performance

QNRX
10/100

QNRX returned -81.93% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

CYCC
10/100

CYCC returned -69.77% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

QNRX
29/100

QNRX receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

CYCC
14/100

CYCC receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

QNRX
10/100

QNRX has missed earnings 5 times in the last 20 quarters.

CYCC
10/100

CYCC has missed earnings 8 times in the last 20 quarters.

Profit

QNRX
10/100

Out of the last 14 quarters, QNRX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

CYCC
10/100

Out of the last 20 quarters, CYCC has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

QNRX
35/100

QNRX has had a lower than average amount of volatility over the last 12 months giving it a score of 35 of 100.

CYCC
48/100

CYCC has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

Analyst Price Targets

QNRX

"Analyst Price Targets" not found for QNRX

CYCC
75/100

1 analysts offer 12-month price targets for CYCC. Together, they have an average target of 0, the most optimistic target put CYCC at 0 within 12-months and the most pessimistic has CYCC at 0.

Dividend

QNRX

"Dividend" not found for QNRX

CYCC
10/100

CYCC's most recent dividend was $0.08 per share, based on a share price of $0.34. It was a payout ratio of -2.36% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Quoin Pharmaceuticals, Ltd. American Depositary Shares Summary

Nasdaq / QNRX

Healthcare

Biotechnology

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Cyclacel Pharmaceuticals, Inc Summary

Nasdaq / CYCC

Healthcare

Biotechnology

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Power up your portfolio